{
  "question_stem": {
    "en": "A 32-year-old man is evaluated for recurrent nausea and vomiting. The patient has nausea and upper abdominal discomfort after meals and feels full even after eating a small amount of food. He also has experienced several episodes of vomiting of undigested food particles but has had no fever or diarrhea. The patient has a history of type 1 diabetes mellitus and diabetic neuropathy. Physical examination shows a clear oropharynx. The abdomen is soft, nondistended, and nontender with no organomegaly. Bowel sounds are normoactive. Stool testing for occult blood is negative. Upper gastrointestinal endoscopy reveals no abnormalities. Treatment with an oral macrolide antibiotic is prescribed, which improves his symptoms. Which of following mechanisms is most likely responsible for the improvement in this patient's symptoms?",
    "zh": "一名32岁男性因反复恶心和呕吐就诊。患者餐后出现恶心和上腹部不适，即使少量进食后也会感到饱胀。他还经历了几次呕吐未消化的食物颗粒的情况，但没有发烧或腹泻。患者有1型糖尿病和糖尿病性神经病变的病史。体格检查显示口咽部清晰。腹部柔软，无膨胀，无压痛，无脏器肿大。肠鸣音正常。大便潜血试验阴性。上消化内镜检查未发现异常。处方口服大环内酯类抗生素，症状有所改善。以下哪种机制最有可能导致该患者的症状改善？"
  },
  "question": {
    "en": "Which of following mechanisms is most likely responsible for the improvement in this patient's symptoms?",
    "zh": "以下哪种机制最有可能导致该患者的症状改善？"
  },
  "options": {
    "A": {
      "en": "Agonistic activity on motilin receptors",
      "zh": "对生长素释放肽受体的激动活性"
    },
    "B": {
      "en": "Blockade of gastrointestinal muscarinic receptors",
      "zh": "阻断胃肠道毒蕈碱受体"
    },
    "C": {
      "en": "Increase in intestinal fluid secretion",
      "zh": "增加肠液分泌"
    },
    "D": {
      "en": "Protective effect on gastric mucosa",
      "zh": "对胃粘膜的保护作用"
    },
    "E": {
      "en": "Suppression of intestinal bacterial growth",
      "zh": "抑制肠道细菌生长"
    }
  },
  "correct_answer": "A",
  "explanation": {
    "en": "This patient with diabetes has postprandial nausea, vomiting of undigested food, bloating, and early satiety, raising strong suspicion for DIABETIC GASTROPARESIS, an autonomic neuropathy of the gastrointestinal tract marked by delayed gastric emptying in the absence of mechanical obstruction (eg, normal esophagogastroduodenoscopy [EGD]). Metoclopramide, a dopamine 2 receptor antagonist, can improve symptoms but is occasionally associated with extrapyramidal side effects (eg, dystonia) and tardive dyskinesia (eg, involuntary movements).\n\nFor patients with gastroparesis who cannot tolerate metoclopramide, erythromycin, a macrolide antibiotic, can be used as an alternate prokinetic agent. The prokinetic effects of erythromycin stem from the ACTIVATION of the MOTILIN RECEPTOR in the smooth muscle of the upper digestive tract, which results in coordinated peristaltic contractions that begin in the stomach and move through the entire upper digestive system (thereby propelling food into the colon).\n\nWhen used as an antibiotic, erythromycin can cause significant abdominal cramping, but in the setting of gastroparesis, the prokinetic effects can be leveraged to improve gastric emptying and ameliorate gastroparesis symptoms. However, the agonist effects of erythromycin diminish over time (tachyphylaxis) so it is generally used for short periods (<4 weeks).\n\n(Choices B and C) Patients with irritable bowel syndrome (IBS) who have significant gastrointestinal bloating symptoms can be treated with antispasmodic medications (eg, dicycloverine) that block gastrointestinal muscarinic receptors. Those with constipation-predominant IBS are sometimes treated with lubiprostone, a chloride channel activator, to increase intestinal fluid secretion. IBS is usually marked by periods of diarrhea and/or constipation and abdominal bloating; early satiety and vomiting of undigested food would be atypical.\n\n(Choice D) Peptic ulcer disease (PUD) is treated with medications (eg, proton pump inhibitor, sucralfate) that have a protective effect on the gastrointestinal mucosa. Although PUD can occasionally cause nausea, vomiting, and early satiety due to gastric outlet obstruction, most patients have significant upper abdominal pain. In addition, an EGD would show a gastric or duodenal ulcer.\n\n(Choice E) Patients with small intestinal bacterial overgrowth (SIBO)—colonization of the small intestine with colonic bacteria—often develop bloating, abdominal discomfort, flatulence, and/or diarrhea. However, early satiety and vomiting of undigested food would be atypical. In addition, SIBO is generally treated with rifaximin or neomycin.\n\nEducational objective: Erythromycin stimulates upper gastrointestinal motility by acting as an agonist on motilin receptors in the muscularis externa. Therefore, it can be used to treat gastroparesis (ie, delayed gastric emptying), a condition that frequently occurs in patients with long standing diabetes mellitus.",
    "zh": "该糖尿病患者出现餐后恶心、呕吐未消化食物、腹胀和早期饱腹感，强烈提示糖尿病性胃轻瘫，这是一种胃肠道的自主神经病变，其特征是在没有机械性梗阻的情况下（例如，正常的食管胃十二指肠镜检查[EGD]）胃排空延迟。 多潘立酮，一种多巴胺2受体拮抗剂，可以改善症状，但偶尔与锥体外系副作用（例如，肌张力障碍）和迟发性运动障碍（例如，不自主运动）相关。\n\n对于无法耐受多潘立酮的胃轻瘫患者，红霉素，一种大环内酯类抗生素，可用作替代促动力剂。 红霉素的促动力作用源于激活上消化道平滑肌中的生长素释放肽受体，这会导致协调的蠕动收缩，从胃开始，贯穿整个上消化系统（从而将食物推入结肠）。\n\n当用作抗生素时，红霉素会引起严重的腹部绞痛，但在胃轻瘫的情况下，可以利用其促动力作用来改善胃排空并缓解胃轻瘫症状。 然而，红霉素的激动剂效应会随着时间的推移而减弱（快速耐受性），因此通常用于短时间 (<4 周)。\n\n(选项 B 和 C) 患有肠易激综合征 (IBS) 且有明显的胃肠胀气症状的患者可用解痉药（例如，双环胺）治疗，这些药物可阻断胃肠道毒蕈碱受体。那些以便秘为主的 IBS 患者有时用鲁比前列酮治疗，这是一种氯离子通道激活剂，可增加肠液分泌。 IBS 通常以腹泻和/或便秘和腹胀为特征；早期饱腹感和呕吐未消化的食物是不典型的。\n\n(选项 D) 消化性溃疡病 (PUD) 用对胃肠粘膜有保护作用的药物（例如，质子泵抑制剂，硫糖铝）治疗。 尽管 PUD 偶尔会因胃出口梗阻而引起恶心、呕吐和早期饱腹感，但大多数患者都有明显的上腹部疼痛。 此外，EGD 会显示胃或十二指肠溃疡。\n\n(选项 E) 小肠细菌过度生长 (SIBO) 患者 — 小肠被结肠细菌定植 — 经常出现腹胀、腹部不适、胀气和/或腹泻。 然而，早期饱腹感和呕吐未消化的食物是不典型的。 此外，SIBO 通常用利福昔明或新霉素治疗。\n\n教育目标：红霉素通过作为生长素释放肽受体激动剂作用于肌肉外层的生长素释放肽受体来刺激上胃肠道蠕动。 因此，它可用于治疗胃轻瘫（即，胃排空延迟），这种情况经常发生在患有长期糖尿病的患者中。"
  },
  "summary": {
    "en": "This question tests knowledge of diabetic gastroparesis and the mechanism of action of erythromycin as a prokinetic agent. It assesses the ability to recognize the clinical presentation of gastroparesis and understand the role of motilin receptors in gastrointestinal motility.\n\nTo solve this question, recognize the patient's symptoms as suggestive of gastroparesis, given the history of diabetes. Recall that erythromycin acts as a motilin receptor agonist to enhance gastric emptying, making option A the most likely mechanism for symptom improvement.",
    "zh": "这个问题测试了对糖尿病性胃轻瘫的了解以及红霉素作为促动力剂的作用机制。 它评估了识别胃轻瘫的临床表现并了解生长素释放肽受体在胃肠道动力学中的作用的能力。\n\n要解决这个问题，鉴于糖尿病病史，将患者的症状识别为提示胃轻瘫。 回忆一下，红霉素作为生长素释放肽受体激动剂可增强胃排空，这使得选项 A 成为症状改善最有可能的机制。"
  },
  "tags": "Diabetic gastroparesis; Erythromycin; Motilin receptors; Gastrointestinal motility; Prokinetic agents; Type 1 diabetes; Diabetic neuropathy; Gastroenterology; Pharmacology",
  "category": "Endo",
  "question_id": "6705",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Endo 23\\6705",
  "extracted_at": "2025-11-05T14:10:14.880523",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:42:31.109774",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}